共 50 条
Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review
被引:8
|作者:
Lominadze, Zurabi
[1
]
Hill, Kareen
[2
]
Shaik, Mohammed Rifat
[3
]
Canakis, Justin P.
[4
]
Bourmaf, Mohammad
[2
]
Adams-Mardi, Cyrus
[4
]
Abutaleb, Ameer
[5
]
Mishra, Lopa
[6
]
Shetty, Kirti
[1
]
机构:
[1] Univ Maryland, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Dept Med, Med Ctr, Baltimore, MD 21201 USA
[3] Univ Maryland, Dept Med, Med Ctr, Midtown Campus, Baltimore, MD 21201 USA
[4] George Washington Univ, Dept Med, Sch Med & Hlth Sci, Washington, DC 20037 USA
[5] George Washington Univ, Dept Surg, Sch Med & Hlth Sci, Washington, DC 20037 USA
[6] Northwell Hlth, Feinstein Inst Med Res, Div Gastroenterol & Hepatol, Cold Spring Harbor Lab, Manhasset, NY 11030 USA
关键词:
hepatocellular carcinoma;
immunotherapy;
liver transplantation;
allograft rejection;
REGULATORY T-CELLS;
CANCER-PATIENTS;
RECURRENCE;
THERAPY;
RISK;
DURVALUMAB;
NIVOLUMAB;
ANTITUMOR;
RESECTION;
MELANOMA;
D O I:
10.3390/ijms24032358
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
The emerging field of immuno-oncology has brought exciting developments in the treatment of hepatocellular carcinoma (HCC). It has also raised urgent questions about the role of immunotherapy in the setting of liver transplantation, both before and after transplant. A growing body of evidence points to the safety and efficacy of immunotherapeutic agents as potential adjuncts for successful down-staging of advanced HCCs to allow successful transplant in carefully selected patients. For patients with recurrent HCC post-transplant, immunotherapy has a limited, yet growing role. In this review, we describe optimal regimens in the setting of liver transplantation.
引用
收藏
页数:16
相关论文